InMed CEO, Eric A. Adams, is asked by Shadd Dales of The Dales Repot whether the cost of rare cannabinoids is scalable enough to entice big consumer product companies.
Read the article and watch the full video at The Dales Report.
InMed CEO, Eric A. Adams, is asked by Shadd Dales of The Dales Repot whether the cost of rare cannabinoids is scalable enough to entice big consumer product companies.
Read the article and watch the full video at The Dales Report.
In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s
There have been major advances in Alzheimer’s disease research and development in the past two years alone. What are those breakthroughs and what’s in development
In this video, InMed’s CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.
© Copyright 2024 InMed Pharmaceuticals Inc.
"*" indicates required fields